GlassScriptPhysician profile
Jeffrey T Zigulis
NPI 1619920535
$900.01
in general payments reported to CMS, 2019-2025
11 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.88 · 2020: $172 · 2021: $273 · 2022: $13.33 · 2023: $68.37 · 2024: $173 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $253.61 | 2021-2025 | Misight Contact Lens, Myday Contact Lens |
| Optovue, INC. | $138.93 | 2021 | |
| Oyster Point Pharma, INC. | $103.35 | 2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $78.19 | 2019-2021 | |
| Optos, INC. | $76.27 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $68.54 | 2024-2025 | |
| Alcon Vision LLC | $49.41 | 2019-2025 | Precision7 |
| Maculogix, INC. | $40.00 | 2021 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Bausch & Lomb Americas INC. | $33.33 | 2022-2024 | Infuse |
| Sun Pharmaceutical Industries INC. | $19.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Zigulis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.